Scope and Methods of the PARADIGM Study and Expert Commentary on Treatment Decision-Making
Shilpa Gupta, MD, describes the scope and methods of the PARADIGM study, which examines recent systemic anti-cancer treatment patterns in la/mUC.
Overview of Locally Advanced/Metastatic Urothelial Carcinoma
Vinit Makkar, MD, provides a brief overview of locally advanced/metastatic urothelial carcinoma (la/mUC), available first-line (1L) and first-line maintenance (1LM) treatment options, and unmet needs in the field.
Therapy Strategies for Primary Myelofibrosis
Raajit Rampal, MD, PhD, shares the treatment options he would consider for the presented clinical scenario.
CRESTONE Trial of Seribantumab in Solid Tumors With NRG1 Fusions: Efficacy Data
Shared insight on key efficacy data from the CRESTONE clinical trial of seribantumab therapy in solid tumors with NRG1 fusions.
CRESTONE Trial of Seribantumab in Solid Tumors With NRG1 Fusions: Trial Design and Safety Data
Expert perspectives on the trial design of and safety data from CRESTONE, which analyzed seribantumab therapy in solid tumors with NRG1 fusions.
Approved Treatments for Myelofibrosis
A review of the approved treatments for myelofibrosis, including dosing guidelines and supporting clinical trial data.
Clinical Scenario: Patient with Primary Myelofibrosis
Dr John Mascarenhas presents a patient case scenario of a 68-year-old woman with a common presentation of primary myelofibrosis.
The JAK/STAT Pathway and Myelofibrosis
Raajit Rampal, MD, describes the JAK-STAT pathway and how it’s fundamental to all types of myelofibrosis.
Patient Profile 3: A 57-Year-Old Woman With Triple-Class Refractory MM
Moving to the last patient profile, expert panelists discuss a patient with triple-class refractory multiple myeloma managed with BCMA-targeting bispecific therapy.
EGFR-Targeted Therapy in NSCLC: Optimizing Sequencing and Combinations
Focusing on the broader treatment armamentarium for EGFR-mutated NSCLC, Sandip Patel, MD, considers possible sequencing and combination strategies.
Optimizing Outcomes in Patients with HER2+ BC with Current and Novel Therapies
A panel of experts discusses factors to consider when selecting treatment for patients with HER2+ mBC including brain metastases, quality of life, and treatment resistance.
Selecting the Appropriate Treatment for Patients with HER2+ mBC in Frontline and Beyond
Focusing discussion on the first clinical scenario, panelists examine currently available first- and second-line treatment approaches for HER2+ mBC.
Treating Transplant-Ineligible NDMM With High-Risk Cytogenetics
Shared insight on the selection of therapy for patients with transplant-ineligible, newly diagnosed multiple myeloma and high-risk cytogenetics.
Targeting Rare EGFR Mutations in NSCLC: Afatinib and Mobocertinib
Sandip Patel, MD, highlights the use of afatinib and mobocertinib, respectively, to treat NSCLC with rare EGFR-mutation variants.
Tony S. Mok, MD, Talks Future Analyses of Capmatinib Plus Pembrolizumab in NSCLC
Tony S. Mok, MD, spoke about future research efforts focused on capmatinib plus pembrolizumab in patients with previously untreated MET-unselected, PD-L1–positive non–small cell lung cancer.
Xiuning Le, MD, PhD, Discusses Who May Benefit Most From Tepotinib in Advanced NSCLC
Xiuning Le, MD, PhD, spoke about which patients with advanced non–small cell lung cancer with high MET-amplification could benefit most from tepotinib based on molecular markers.
Shubham Pant, MD, Highlights the Potential of ELI-002 2P to Treat MRD in KRAS-Mutant Solid Malignancies
Shubham Pant, MD, spoke to the potential of ELI-002 2P as a treatment for minimal residual disease positivity in patients with KRAS-mutant solid tumors.
Benjamin Cooper, MD, Remarks on Future Analyses of TAK-676 Plus Pembrolizumab in Solid Tumors Undergoing Radiation
Benjamin Cooper, MD, discussed potential future studies exploring TAK-676 plus pembrolizumab after radiation for those with solid tumors.
Roger Li, MD, Examines the Safety Profile of CG0070 Plus Pembrolizumab in BCG-Unresponsive NMIBC
Roger Li, MD, spoke about the safety profile of CG0070 plus pembrolizumab for patients with non–muscle invasive bladder cancer.
Catherine S. Diefenbach, MD, Discusses Gaps Filled by Approval of Liso-Cel in Second-Line Relapsed/Refractory LBCL
Catherine S. Diefenbach, MD, spoke about the approval of lisocabtagene maraleucel for patients with relapsed/refractory large B-cell lymphoma who do not have chemotherapy-sensitive disease.
